Janux Therapeutics, Inc.
JANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001817713
No open-market purchases or sales by Janux Therapeutics, Inc. insiders were filed in the last 90 days; 197 institutions reported holding it in 13F filings for Q2 2026, worth $933.4M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Janux Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 30
- +30 vs. Q1 2021
- Shares held
- 24.7M
- +24.7M vs. Q1 2021
- Total value
- $614.5M
- +$614.5M vs. Q1 2021
- New holders
- 30
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $933.4M |
| Q1 2026 | 190 | $827.8M |
| Q4 2025 | 176 | $860.0M |
| Q3 2025 | 174 | $1.59B |
| Q2 2025 | 174 | $1.51B |
| Q1 2025 | 181 | $1.81B |
| Q4 2024 | 216 | $3.43B |
| Q3 2024 | 160 | $2.07B |
| Q2 2024 | 155 | $1.87B |
| Q1 2024 | 121 | $1.59B |
| Q4 2023 | 64 | $359.5M |
| Q3 2023 | 57 | $354.0M |
| Q2 2023 | 54 | $362.1M |
| Q1 2023 | 48 | $369.5M |
| Q4 2022 | 50 | $381.3M |
| Q3 2022 | 49 | $400.3M |
| Q2 2022 | 44 | $353.0M |
| Q1 2022 | 47 | $407.1M |
| Q4 2021 | 46 | $541.6M |
| Q3 2021 | 45 | $571.2M |
| Q2 2021 | 30 | $614.5M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Janux Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 8,670,644 | $216.3M | 3.47% | +8,670,644 | New |
| OrbiMed Advisors LLC | 3,466,386 | $86.5M | 0.88% | +3,466,386 | New |
| Janus Henderson Group PLC | 2,668,207 | $64.5M | 0.03% | +2,668,207 | New |
| Citadel Advisors LLC | 1,886,712 | $46.2M | 0.05% | +1,886,712 | New |
| FMR LLC | 1,843,564 | $46.0M | 0.00% | +1,843,564 | New |
| EcoR1 Capital, LLC | 1,411,975 | $35.2M | 1.32% | +1,411,975 | New |
| BVF Inc | 1,176,681 | $29.4M | 1.10% | +1,176,681 | New |
| Deerfield Management Company, L.P. (Series C) | 700,000 | $17.5M | 0.31% | +700,000 | New |
| Samsara BioCapital, LLC | 607,949 | $15.2M | 1.99% | +607,949 | New |
| Logos Global Management LP | 547,122 | $13.7M | 1.17% | +547,122 | New |
| Adage Capital Partners GP, L.L.C. | 450,000 | $11.2M | 0.02% | +450,000 | New |
| 5AM Venture Management, LLC | 446,266 | $11.1M | 2.80% | +446,266 | New |
| Woodline Partners LP | 334,260 | $8.34M | 0.16% | +334,260 | New |
| BlackRock Inc. | 109,947 | $2.74M | 0.00% | +109,947 | New |
| Citigroup Inc | 86,695 | $2.16M | 0.00% | +86,695 | New |
| Millennium Management LLC | 75,257 | $1.88M | 0.00% | +75,257 | New |
| Goldman Sachs Group Inc | 69,000 | $1.72M | 0.00% | +69,000 | New |
| LMR Partners LLP | 57,000 | $1.42M | 0.02% | +57,000 | New |
| Pinz Capital Management, LP | 32,100 | $801.0K | 0.24% | +32,100 | New |
| Vanguard Group Inc | 28,976 | $723.0K | 0.00% | +28,976 | New |
| ExodusPoint Capital Management, LP | 24,567 | $613.0K | 0.01% | +24,567 | New |
| Geode Capital Management, LLC | 22,017 | $549.0K | 0.00% | +22,017 | New |
| Qube Research & Technologies Ltd | 14,309 | $357.0K | 0.00% | +14,309 | New |
| Wellington Management Group LLP | 9,165 | $229.0K | 0.00% | +9,165 | New |
| Bank of America Corp | 2,048 | $52.0K | 0.00% | +2,048 | New |
| Royal Bank of Canada | 1,300 | $32.0K | 0.00% | +1,300 | New |
| JPMorgan Chase & Co | 646 | $16.0K | 0.00% | +646 | New |
| UBS Group AG | 353 | $9.00K | 0.00% | +353 | New |
| Morgan Stanley | 100 | $2.00K | 0.00% | +100 | New |
| US Bancorp | 7 | $0 | 0.00% | +7 | New |